Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank59
3Y CAGR+7.1%
5Y CAGR-50.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+7.1%/yr
Quarterly compound
5Y CAGR
-50.2%/yr
Recent acceleration
Percentile
P59
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 22.64% |
| Q3 2025 | 79.11% |
| Q2 2025 | -35.35% |
| Q1 2025 | -13.59% |
| Q4 2024 | 54.68% |
| Q3 2024 | 106.79% |
| Q2 2024 | -56.89% |
| Q1 2024 | 26.45% |
| Q4 2023 | -22.70% |
| Q3 2023 | 98.10% |
| Q2 2023 | -23.14% |
| Q1 2023 | 5.47% |
| Q4 2022 | 18.41% |
| Q3 2022 | 73.11% |
| Q2 2022 | -15.84% |
| Q1 2022 | -42.08% |
| Q4 2021 | -32.22% |
| Q3 2021 | 230.01% |
| Q2 2021 | -36.72% |
| Q1 2021 | 14.49% |
| Q4 2020 | 736.95% |
| Q3 2020 | 84.70% |
| Q2 2020 | 168.00% |
| Q1 2020 | 81.81% |
| Q4 2019 | 10.01% |
| Q3 2019 | -19.37% |
| Q2 2019 | -460.26% |
| Q1 2019 | -142.29% |
| Q4 2018 | 155.28% |
| Q3 2018 | -0.37% |
| Q2 2018 | 14.97% |
| Q1 2018 | -114.47% |
| Q4 2017 | 656.45% |
| Q3 2017 | 219.20% |
| Q2 2017 | 24.32% |
| Q1 2017 | -42.44% |
| Q4 2016 | -80.24% |
| Q3 2016 | 31.90% |
| Q2 2016 | 1.37% |
| Q1 2016 | 14.31% |